12.35
+1.42(+12.99%)
Currency In USD
| Previous Close | 10.93 |
| Open | 10.92 |
| Day High | 12.5 |
| Day Low | 10.51 |
| 52-Week High | 76 |
| 52-Week Low | 4.56 |
| Volume | 36,320 |
| Average Volume | 29,785 |
| Market Cap | 57.97M |
| PE | -4.1 |
| EPS | -3.01 |
| Moving Average 50 Days | 13.37 |
| Moving Average 200 Days | 11.72 |
| Change | 1.42 |
If you invested $1000 in MiNK Therapeutics, Inc. (INKT) since IPO date, it would be worth $102.92 as of December 04, 2025 at a share price of $12.35. Whereas If you bought $1000 worth of MiNK Therapeutics, Inc. (INKT) shares 3 years ago, it would be worth $486.22 as of December 04, 2025 at a share price of $12.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
GlobeNewswire Inc.
Nov 20, 2025 4:42 PM GMT
MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cellsActivates multiple immune pathways to generate potent, lasting anti-tumor activity in l
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
GlobeNewswire Inc.
Nov 14, 2025 12:30 PM GMT
New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive funding from NIH- and philanthropic grantsLaunching Ph
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune remodeling underscore agenT-797’s potential to